Previous studies showed that the treatment with the glioma inhibitory drug temozolomide (TMZ) resulted in Jarid2 downregulation and CCND1 upregulation within glioma tissues of different grades, and further studies showed that JARID2 negatively regulates CCND1 expression by increasing the H3K27me3 level on the CCND1 promoter in leukemia cell [62,63]. This evidence concerns the gene JARID2 and leukemia.